Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

BACKGROUND: The global Phase III IMpower132 study evaluating atezolizumab plus pemetrexed and carboplatin or cisplatin (APP) versus pemetrexed plus carboplatin or cisplatin (PP) for first‐line treatment of non‐squamous advanced non‐small cell lung cancer (NSCLC) met its co‐primary progression‐free s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Fang, Jian, Wang, Ziping, Fan, Yun, Liu, Yunpeng, He, Jianxing, Zhou, Jianying, Hu, Jie, Xia, Jinjing, Liu, Wenxin, Shi, Jane, Yi, Jing, Cao, Lejie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939192/
https://www.ncbi.nlm.nih.gov/pubmed/36052772
http://dx.doi.org/10.1002/cam4.5144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939192/
https://www.ncbi.nlm.nih.gov/pubmed/36052772
http://dx.doi.org/10.1002/cam4.5144

Ejemplares similares